{
  "schemaVersion": 2,
  "eyebrow": "Dermatologic Oncology",
  "title": "Basal Cell Carcinoma",
  "summary": "Manage basal cell carcinoma by confirming clinically uncertain lesions histologically, separating low-risk from high-risk or recurrent tumors, selecting margin-controlled surgery when tissue preservation and clearance matter, and escalating unresectable disease to Hedgehog inhibition or cemiplimab.",
  "seoDescription": "Physician guide to basal cell carcinoma diagnosis, risk stratification, surgery, nonsurgical options, advanced-disease systemic therapy, and surveillance.",
  "clinicalQuestion": "How should physicians diagnose, risk-stratify, treat, and surveil basal cell carcinoma?",
  "specialty": "Dermatology",
  "audience": "U.S. physicians and medical trainees",
  "tags": [
    "basal cell carcinoma",
    "Mohs micrographic surgery",
    "hedgehog inhibitor",
    "vismodegib",
    "sonidegib",
    "cemiplimab",
    "nonmelanoma skin cancer"
  ],
  "keyTakeaways": [
    "Biopsy clinically equivocal lesions; dermoscopy can support diagnosis and may help predict histopathologic subtype, but histopathology establishes the diagnosis when uncertainty remains. [5][15]",
    "Use margin-controlled surgery for high-risk, recurrent, or anatomically critical-site BCC; complete surgical treatment is first-line for most tumors. [5][6]",
    "Features that should move a lesion out of routine low-risk management include diameter greater than 2 cm, central-face, ear, or scalp location, poorly defined borders, recurrence, morpheaform, infiltrative, micronodular, or basosquamous histology, and perineural invasion. [11][23]",
    "Reserve topical and destructive approaches for carefully selected low-risk superficial BCC; photodynamic therapy is an option for superficial and low-risk nodular tumors. [4][6]",
    "For locally advanced or metastatic BCC not amenable to curative local therapy, use a Hedgehog pathway inhibitor; cemiplimab is FDA-indicated after prior Hedgehog inhibitor therapy or when a Hedgehog inhibitor is not appropriate. [1][6][17]"
  ],
  "sections": [
    {
      "id": "diagnostic-confirmation",
      "eyebrow": "Initial Assessment",
      "heading": "Confirm BCC and identify features that change local treatment",
      "intro": "Document features that determine whether definitive treatment requires conventional or margin-controlled surgery.",
      "paragraphs": [
        "Perform focused lesion examination with dermoscopy and document greatest clinical diameter, anatomic site, border definition, prior treatment, and whether the lesion is primary or recurrent. Dermoscopy is useful for BCC diagnosis and may help predict histopathologic subtype, but biopsy is required when clinical and dermoscopic findings are equivocal. [5][15]",
        "Choose a biopsy approach that will provide histologic confirmation and subtype information without compromising definitive management. The pathology report should be reviewed specifically for aggressive growth patterns—morpheaform, infiltrative, micronodular, or basosquamous differentiation—and for perineural invasion, because each shifts management toward complete margin assessment and closer surveillance. [11][12][23]",
        "Do not use routine TNM staging for ordinary localized BCC. Formal staging or additional extent assessment becomes relevant when there is advanced local disease, suspected nodal or distant disease, or concern for invasion of parotid gland, muscle, deep soft tissue, orbit, bone, or perineural structures. In these settings, obtain preoperative imaging directed to the threatened structure and plan treatment with dermatologic surgery, surgical oncology, radiation oncology, or a multidisciplinary tumor board. [11][12]"
      ],
      "bullets": [
        "Record prior BCCs and perform a complete skin examination; patients with one skin cancer remain at increased risk for additional skin cancers and precancerous lesions. [11]",
        "Use photographic or digital site documentation when following multiple lesions, recurrent tumors, or patients with extensive field cancerization. [11]",
        "Treat neurologic symptoms, radiologic perineural involvement, or pathology-confirmed perineural invasion as escalation triggers because perineural spread can extend beyond clinically apparent margins. [12]"
      ],
      "subsections": [],
      "table": {
        "caption": "Clinical and histologic features that favor margin-controlled management or assessment for deeper extension. [11][12][23]",
        "columns": [
          "Finding",
          "Interpretation",
          "Next action"
        ],
        "rows": [
          [
            "Diameter >2 cm",
            "High-risk recurrence feature. [11][23]",
            "Plan definitive surgical clearance; assess whether location or extent favors micrographic surgery. [6][11]"
          ],
          [
            "Central face, ear, or scalp",
            "High-risk location; central facial and auricular tumors have increased recurrence concern. [11][23]",
            "Favor micrographically controlled surgery when feasible. [6]"
          ],
          [
            "Poorly defined borders or recurrent tumor",
            "Clinical features associated with higher recurrence risk and occult extension. [11]",
            "Use margin-controlled surgery rather than destructive treatment. [6][11]"
          ],
          [
            "Morpheaform, infiltrative, micronodular, or basosquamous subtype",
            "Aggressive histology associated with high-risk behavior. [11][23]",
            "Use complete margin assessment; discuss difficult cases in a multidisciplinary setting. [6]"
          ],
          [
            "Perineural invasion or symptoms suggesting neural involvement",
            "May indicate deeper extension beyond visible margins. [12]",
            "Obtain anatomy-directed imaging when clinically indicated and coordinate multidisciplinary treatment. [11][12]"
          ]
        ]
      }
    },
    {
      "id": "local-treatment-selection",
      "eyebrow": "Definitive Local Therapy",
      "heading": "Match treatment to recurrence risk, anatomy, and need for margin control",
      "intro": "Surgical clearance is the default; nonsurgical therapy is a selection-dependent alternative rather than a substitute for high-risk disease control.",
      "paragraphs": [
        "Offer complete surgery as first-line treatment for BCC. For high-risk or recurrent tumors and tumors at critical anatomic sites, micrographically controlled surgery should be offered because it provides real-time margin assessment while preserving uninvolved tissue. [5][6]",
        "Use conventional surgical excision with margin evaluation for appropriately selected localized tumors when anatomic location and histology do not require micrographic control. Surgery, including standard excision and Mohs micrographic surgery, is the principal curative approach for localized BCC; reported recurrence-free rates across properly selected local modalities range from 85% to 95%. [3][17]",
        "Restrict curettage and electrodesiccation, cryotherapy, topical imiquimod, topical 5-fluorouracil, and other destructive approaches to low-risk superficial BCC when histologic margin control is not required. These modalities should not be used as routine therapy for recurrent, poorly defined, aggressive-subtype, or critical-site tumors because they do not provide the same complete margin assessment. [4][6][17]",
        "Consider photodynamic therapy for superficial BCC and selected low-risk nodular BCC when surgery is not preferred or when a nonsurgical approach is appropriate. The tradeoff is that surgery remains standard first-line treatment, whereas photodynamic therapy is a selection-dependent alternative for low-risk disease. [6][17]"
      ],
      "bullets": [
        "Use radiotherapy as a definitive local alternative for patients who are not surgical candidates or who decline surgery. [5][6][17]",
        "After incomplete excision or clinically evident recurrence, reassess histology, site, and extent rather than repeating a low-control modality; recurrent disease is a specific indication to favor micrographically controlled surgery. [6][11]",
        "Refer difficult-to-treat BCC—particularly lesions threatening orbit, bone, major nerves, or functionally critical structures—for multidisciplinary discussion before committing to morbid surgery, radiotherapy, or systemic therapy. [5][6]"
      ],
      "subsections": [],
      "table": {
        "caption": "Local-treatment selection for BCC. [4][5][6][17]",
        "columns": [
          "Clinical setting",
          "Preferred approach",
          "Alternative or limiting consideration"
        ],
        "rows": [
          [
            "Most primary localized BCC",
            "Complete surgical excision. [5][6]",
            "Conventional excision is appropriate when complete margins can be obtained without a need for micrographic control. [17]"
          ],
          [
            "High-risk, recurrent, or critical-site BCC",
            "Micrographically controlled surgery. [5][6]",
            "Use multidisciplinary planning if extent threatens function or major structures. [5][6]"
          ],
          [
            "Low-risk superficial BCC",
            "Topical imiquimod, topical 5-fluorouracil, or destructive therapy can be considered. [4][6][17]",
            "Avoid these approaches when aggressive histology, recurrence, poorly defined borders, or critical-site location requires margin control. [6][11]"
          ],
          [
            "Superficial or low-risk nodular BCC",
            "Photodynamic therapy can be effective. [6]",
            "Surgery remains standard first-line therapy. [5][6]"
          ],
          [
            "Declines surgery or is not a surgical candidate",
            "Radiotherapy is a valid local alternative. [5][6][17]",
            "Do not use radiotherapy as a substitute for appropriate surgical assessment when surgery is feasible and preferred. [6]"
          ]
        ]
      }
    },
    {
      "id": "advanced-disease",
      "eyebrow": "Locally Advanced or Metastatic Disease",
      "heading": "Escalate unresectable BCC to systemic therapy after determining whether curative local treatment remains feasible",
      "intro": "Advanced BCC requires a resectability and radiation assessment before systemic treatment is selected.",
      "paragraphs": [
        "Classify BCC as locally advanced when complete surgery or curative radiotherapy is not feasible without unacceptable morbidity, and as metastatic when nodal or distant spread is present. Before systemic therapy, define local extent with anatomy-directed imaging when deep soft tissue, muscle, parotid, orbit, bone, or perineural involvement is suspected. [11][17]",
        "Offer a Hedgehog pathway inhibitor—vismodegib or sonidegib—for locally advanced or metastatic BCC. These agents are the recommended systemic first-line class for advanced disease; prolonged Smoothened inhibitor therapy can be followed by resistance. [6][20]",
        "Use cemiplimab for adults with locally advanced or metastatic BCC previously treated with a Hedgehog pathway inhibitor or for whom a Hedgehog pathway inhibitor is not appropriate. The FDA indication is supported by Study 1620, which enrolled advanced BCC after progression on a Hedgehog inhibitor, absence of objective response after 9 months of Hedgehog inhibitor therapy, or intolerance of prior Hedgehog inhibitor therapy. [1][2]",
        "Assess immunotherapy candidacy carefully in patients with prior solid-organ transplantation, active autoimmune disease requiring systemic immunosuppression, or chronic viral infection because these populations were excluded from the pivotal advanced-BCC cemiplimab study. Discuss systemic treatment selection in a multidisciplinary setting when local therapy, radiation, and drug toxicities have competing functional consequences. [1][5][6]"
      ],
      "bullets": [
        "Do not default to cemiplimab before determining whether Hedgehog inhibition is contraindicated, inappropriate, intolerable, or unsuccessful; cemiplimab is positioned after or instead of Hedgehog inhibition under its FDA indication. [1][2]",
        "Reassess resectability and local-control options after systemic response when organ-preserving surgery or radiation may become feasible; difficult-to-treat disease warrants tumor-board review. [5][6]",
        "Document performance status and comorbidities before systemic treatment; Study 1620 excluded patients with ECOG performance status 2 or greater. [1]"
      ],
      "subsections": [],
      "table": {
        "caption": "Systemic-therapy pathway for advanced BCC. [1][2][6][20]",
        "columns": [
          "Situation",
          "Systemic option",
          "Decision constraint"
        ],
        "rows": [
          [
            "Locally advanced or metastatic BCC not curable with local modalities",
            "Hedgehog pathway inhibitor: vismodegib or sonidegib. [6][20]",
            "Consider potential resistance with prolonged Smoothened inhibitor therapy. [20]"
          ],
          [
            "Progression during Hedgehog inhibitor therapy",
            "Cemiplimab. [1][2][6]",
            "FDA-indicated for locally advanced or metastatic BCC after prior Hedgehog inhibitor treatment. [1][2]"
          ],
          [
            "No objective response after 9 months of Hedgehog inhibitor therapy",
            "Cemiplimab may be used. [1][2]",
            "This criterion was included in the advanced-BCC cemiplimab study population. [1][2]"
          ],
          [
            "Hedgehog inhibitor intolerance, contraindication, or inappropriateness",
            "Cemiplimab. [1][2][6]",
            "Evaluate autoimmune disease, transplant history, and immunosuppression in treatment planning. [1]"
          ]
        ]
      }
    },
    {
      "id": "surveillance-prevention",
      "eyebrow": "After Treatment",
      "heading": "Use lifelong skin surveillance and a low biopsy threshold for new or recurrent lesions",
      "intro": "Follow-up should target local recurrence, new keratinocyte cancers, and delayed recognition of high-risk extension.",
      "paragraphs": [
        "Perform long-term, often lifelong follow-up after BCC, with closer surveillance for patients with multiple, recurrent, or high-risk tumors. At each visit, examine the treated site for recurrence and perform a complete skin examination because subsequent skin cancers and precancerous lesions are common in this population. [11]",
        "Maintain a low threshold to biopsy a new lesion within or adjacent to a prior treatment site, especially after topical, destructive, or radiation-based treatment where histologic margins were not assessed. Recurrent BCC, poorly defined borders, and aggressive histology should redirect management to complete margin-controlled treatment rather than repeated empiric destructive therapy. [6][11]",
        "For tumors with perineural invasion, monitor for new pain, paresthesia, weakness, or other focal neurologic symptoms and obtain imaging when symptoms or examination raise concern for clinical perineural spread. Perineural invasion can precede symptoms and is associated with a greater likelihood of extension beyond surgical margins. [12]"
      ],
      "bullets": [
        "Document treated sites photographically when recurrence detection will be clinically difficult or when patients have multiple prior BCCs. [11]",
        "Reassess for deep-structure involvement before reoperation when recurrent disease involves the central face, ear, scalp, orbit, parotid region, or a symptomatic nerve distribution. [11][12]",
        "Continue surveillance after systemic therapy because advanced BCC management may require sequential systemic, surgical, and radiation decisions. [5][6]"
      ],
      "subsections": [],
      "table": {
        "caption": "Surveillance triggers that require a change in management. [11][12]",
        "columns": [
          "Follow-up finding",
          "Interpretation",
          "Action"
        ],
        "rows": [
          [
            "New lesion or change at a prior treatment site",
            "Possible local recurrence or new primary BCC. [11]",
            "Perform prompt clinical assessment and maintain a low threshold for biopsy. [11]"
          ],
          [
            "Recurrent lesion with poorly defined borders",
            "Higher-risk local behavior. [11]",
            "Plan margin-controlled surgery when feasible. [6][11]"
          ],
          [
            "Pain, paresthesia, weakness, or other focal neurologic symptom",
            "Possible clinical perineural involvement. [12]",
            "Obtain directed imaging and coordinate multidisciplinary management. [11][12]"
          ],
          [
            "Multiple or high-risk prior BCCs",
            "Persistent risk for additional skin cancers. [11]",
            "Continue long-term complete skin examinations and lesion-site documentation. [11]"
          ]
        ]
      }
    }
  ],
  "faq": [],
  "references": [
    {
      "number": 1,
      "title": "These highlights do not include all the information needed to use LIBTAYO safely and effectively. See full prescribing information for LIBTAYO. \n       LIBTAYO® (cemiplimab-rwlc) injection, for intravenous use  Initial U.S. Approval: 2018",
      "detail": "dailymed.nlm.nih.gov",
      "url": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4347ae1f-d397-4f18-8b70-03897e1c054a",
      "authors": "dailymed.nlm.nih.gov",
      "host": "dailymed.nlm.nih.gov"
    },
    {
      "number": 2,
      "title": "LIBTAYO",
      "detail": "dailymed.nlm.nih.gov",
      "url": "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=4347ae1f-d397-4f18-8b70-03897e1c054a&type=pdf",
      "authors": "dailymed.nlm.nih.gov",
      "host": "dailymed.nlm.nih.gov"
    },
    {
      "number": 3,
      "title": "Guidelines of care for the management of basal cell carcinoma",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S019096221732529X",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 4,
      "title": "Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines - ScienceDirect",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S0959804919303624",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 5,
      "title": "Current management of nonmelanoma skin cancers",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S0011384024001266",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 6,
      "title": "European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma—update 2023",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S0959804923003568",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 7,
      "title": "Beyond Mohs surgery and excisions: A focused review of treatment options for subtypes of basal cell carcinoma - Altun - 2021 - Dermatologic Therapy - Wiley Online Library",
      "detail": "onlinelibrary.wiley.com",
      "url": "https://onlinelibrary.wiley.com/doi/abs/10.1111/dth.14476",
      "authors": "onlinelibrary.wiley.com",
      "host": "onlinelibrary.wiley.com"
    },
    {
      "number": 8,
      "title": "Keratinocytic skin cancers—Update on the molecular biology",
      "detail": "acsjournals.onlinelibrary.wiley.com",
      "url": "https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.34635",
      "authors": "acsjournals.onlinelibrary.wiley.com",
      "host": "acsjournals.onlinelibrary.wiley.com"
    },
    {
      "number": 9,
      "title": "Known and new facts on basal cell carcinoma",
      "detail": "onlinelibrary.wiley.com",
      "url": "https://onlinelibrary.wiley.com/doi/full/10.1111/ddg.14580",
      "authors": "onlinelibrary.wiley.com",
      "host": "onlinelibrary.wiley.com"
    },
    {
      "number": 10,
      "title": "Comprehensive Insights Into Basal Cell Carcinoma",
      "detail": "onlinelibrary.wiley.com",
      "url": "https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.71448",
      "authors": "onlinelibrary.wiley.com",
      "host": "onlinelibrary.wiley.com"
    },
    {
      "number": 11,
      "title": "Basal Cell Carcinoma - StatPearls - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK482439",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov"
    },
    {
      "number": 12,
      "title": "Basal Cell Carcinoma Perineural Invasion and Suggestive Signs of Perineural Invasion—Findings and Perspectives",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10303443",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 13,
      "title": "Basal Cell Carcinoma",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3385325",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 14,
      "title": "Management Approaches for High-Risk Cutaneous Squamous Cell Carcinoma with Perineural Invasion: An Updated Review - PMC",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11416415",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 15,
      "title": "The relation between dermoscopy and histopathology of basal ...",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4516090",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 16,
      "title": "Cutaneous Squamous Cell Carcinoma - StatPearls - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK441939",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov"
    },
    {
      "number": 17,
      "title": "Skin Cancer Treatment (PDQ®) - NCI",
      "detail": "tools.cdc.gov",
      "url": "https://tools.cdc.gov/podcasts/download.asp?m=343872&c=343882",
      "authors": "tools.cdc.gov",
      "host": "tools.cdc.gov"
    },
    {
      "number": 18,
      "title": "Basal cell carcinoma: an evidence-based treatment update",
      "detail": "pubmed.ncbi.nlm.nih.gov",
      "url": "https://pubmed.ncbi.nlm.nih.gov/24733429",
      "authors": "pubmed.ncbi.nlm.nih.gov",
      "host": "pubmed.ncbi.nlm.nih.gov"
    },
    {
      "number": 19,
      "title": "Results - Treatments for Basal Cell and Squamous Cell Carcinoma of the Skin - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK487557",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov"
    },
    {
      "number": 20,
      "title": "Evaluation and Treatment of Skin Cancer in Patients With Immunosuppression - StatPearls - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/sites/books/n/statpearls/article-169493",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov"
    },
    {
      "number": 21,
      "title": "Management of basal cell carcinoma with pulmonary ...",
      "detail": "pubmed.ncbi.nlm.nih.gov",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36599494",
      "authors": "pubmed.ncbi.nlm.nih.gov",
      "host": "pubmed.ncbi.nlm.nih.gov"
    },
    {
      "number": 22,
      "title": "Guidelines for the diagnosis and treatment of basal cell carcinoma: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S2059702923012784",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 23,
      "title": "Basal Cell Carcinoma Cell - an overview",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/topics/medicine-and-dentistry/basal-cell-carcinoma-cell",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 24,
      "title": "European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S0959804920300186",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    }
  ],
  "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.",
  "citations": [
    {
      "number": 1,
      "title": "These highlights do not include all the information needed to use LIBTAYO safely and effectively. See full prescribing information for LIBTAYO. \n       LIBTAYO® (cemiplimab-rwlc) injection, for intravenous use  Initial U.S. Approval: 2018",
      "detail": "dailymed.nlm.nih.gov",
      "url": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4347ae1f-d397-4f18-8b70-03897e1c054a",
      "authors": "dailymed.nlm.nih.gov",
      "host": "dailymed.nlm.nih.gov",
      "snippet": "## 14.2 Basal Cell Carcinoma (BCC)\n\nThe efficacy of LIBTAYO in 138 patients with advanced basal cell carcinoma (BCC) [unresectable locally advanced (laBCC) or metastatic (nodal or distant) (mBCC)] who had progressed on hedgehog pathway inhibitor (HHI) therapy, had not had an objective response after",
      "score": 0.7045877
    },
    {
      "number": 2,
      "title": "LIBTAYO",
      "detail": "dailymed.nlm.nih.gov",
      "url": "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=4347ae1f-d397-4f18-8b70-03897e1c054a&type=pdf",
      "authors": "dailymed.nlm.nih.gov",
      "host": "dailymed.nlm.nih.gov",
      "snippet": "in 138 patients with advanced basal cell carcinoma (BCC) [unresectable locally advanced (laBCC) or metastatic (nodal or distant) (mBCC)] who had progressed on hedgehog pathway inhibitor (HHI) therapy, had not had an objective response after 9 months on HHI therapy, or were intolerant of prior HHI th",
      "score": 0.66464967
    },
    {
      "number": 3,
      "title": "Guidelines of care for the management of basal cell carcinoma",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S019096221732529X",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "Basal cell carcinoma (BCC) is the most common form of human cancer, with a continually increasing annual incidence in the United States. When diagnosed early, the majority of BCCs are readily treated with office-based therapy, which is highly curative. In these evidence-based guidelines of care, we ",
      "score": 0.62770075
    },
    {
      "number": 4,
      "title": "Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines - ScienceDirect",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S0959804919303624",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "### J Am Acad Dermatol (2007) \n   M. Haedersdal _et al._\n### Translational medicine in the field of ablative fractional laser (AFXL)-assisted drug delivery: a critical review from basics to current clinical status\n\n### J Am Acad Dermatol (2016) \n   M.H. Roozeboom _et al._\n### Fractionated 5-aminolev",
      "score": 0.6188962
    },
    {
      "number": 5,
      "title": "Current management of nonmelanoma skin cancers",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S0011384024001266",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "by MM Dugan · 2025 · Cited by 14 — Risk stratification of basal cell carcinoma and squamous cell carcinoma based on risk factors for recurrence as determined by the National Comprehensive Cancer",
      "score": 0.5883458
    },
    {
      "number": 6,
      "title": "European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma—update 2023",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S0959804923003568",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "controlled surgery shall be offered in high-risk and recurrent BCC, and BCC located on critical anatomical sites. Topical therapies and destructive approaches can be considered in patients with low-risk superficial BCC. Photodynamic therapy is an effective treatment for superficial and low-risk nodu",
      "score": 0.57666177
    },
    {
      "number": 7,
      "title": "Beyond Mohs surgery and excisions: A focused review of treatment options for subtypes of basal cell carcinoma - Altun - 2021 - Dermatologic Therapy - Wiley Online Library",
      "detail": "onlinelibrary.wiley.com",
      "url": "https://onlinelibrary.wiley.com/doi/abs/10.1111/dth.14476",
      "authors": "onlinelibrary.wiley.com",
      "host": "onlinelibrary.wiley.com",
      "snippet": "Basal cell carcinoma (BCC) is the most common nonmelanoma skin cancer. * 1Trakatelli M, Morton C, Nagore E, et al. 10.1016/j.jaad.2017.10.006PubMed Web of Science® Google Scholar. Nonsurgical options for the treatment of basal cell carcinoma. Treatment of basal cell carcinoma with curettage alone. 1",
      "score": 0.8315952
    },
    {
      "number": 8,
      "title": "Keratinocytic skin cancers—Update on the molecular biology",
      "detail": "acsjournals.onlinelibrary.wiley.com",
      "url": "https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.34635",
      "authors": "acsjournals.onlinelibrary.wiley.com",
      "host": "acsjournals.onlinelibrary.wiley.com",
      "snippet": "by TS Win · 2023 · Cited by 10 — Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial",
      "score": 0.6342494
    },
    {
      "number": 9,
      "title": "Known and new facts on basal cell carcinoma",
      "detail": "onlinelibrary.wiley.com",
      "url": "https://onlinelibrary.wiley.com/doi/full/10.1111/ddg.14580",
      "authors": "onlinelibrary.wiley.com",
      "host": "onlinelibrary.wiley.com",
      "snippet": "by M Seidl‐Philipp · 2021 · Cited by 100 — In Europe, hedgehog inhibitors (HHI) are currently the only drug class approved for systemic therapy of BCC [87]. The PD1 inhibitor cemiplimab ...Read more",
      "score": 0.59457535
    },
    {
      "number": 10,
      "title": "Comprehensive Insights Into Basal Cell Carcinoma",
      "detail": "onlinelibrary.wiley.com",
      "url": "https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.71448",
      "authors": "onlinelibrary.wiley.com",
      "host": "onlinelibrary.wiley.com",
      "snippet": "by S Levit · 2025 · Cited by 2 — Treatment options range from Mohs micrographic surgery, and advanced systemic therapies including sonic hedgehog and PD- 1 inhibi- tors for",
      "score": 0.5510187
    },
    {
      "number": 11,
      "title": "Basal Cell Carcinoma - StatPearls - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK482439",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov",
      "snippet": "BCC is primarily staged based on tumor size, location, histologic subtype, and high-risk features. Unlike many other malignancies, formal tumor, node, metastasis (TNM) staging is less commonly applied for BCC due to its very low metastatic potential. High-risk features include tumor diameter greater",
      "score": 0.82728493
    },
    {
      "number": 12,
      "title": "Basal Cell Carcinoma Perineural Invasion and Suggestive Signs of Perineural Invasion—Findings and Perspectives",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10303443",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "Perineural invasion (PNI) is a tumor feature which indicates a poor patient prognosis, being a mechanism for tumor dissemination; it is a feature of high-risk tumors (due to the decreased chances of tumor eradication that PNI implies) which needs to be detected as early as possible in order to avoid",
      "score": 0.7511561
    },
    {
      "number": 13,
      "title": "Basal Cell Carcinoma",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3385325",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "## .\n\n- TX: primary tumor cannot be assessed.- T0: no evidence of primary tumor.- Tis: carcinoma _in situ_.- T1: carcinoma less than 2 cm in greatest dimension, with less than 2 high-risk features.- T2: carcinoma greater than 2 cm in greatest dimension, or a tumor of any size with at least 2 high-ri",
      "score": 0.7500592
    },
    {
      "number": 14,
      "title": "Management Approaches for High-Risk Cutaneous Squamous Cell Carcinoma with Perineural Invasion: An Updated Review - PMC",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11416415",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "## Staging Systems and Risk’ Categories\n\nThe diagnosis of cSCC relies on clinical characteristics, confirmed through histological analysis. In cases with suspicious lesions, it is crucial to perform a biopsy or excision for histopathological confirmation . This procedure is essential for accurate pr",
      "score": 0.72465646
    },
    {
      "number": 15,
      "title": "The relation between dermoscopy and histopathology of basal ...",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4516090",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "by N Emiroglu · 2015 · Cited by 68 — dermoscopy can be used as a valuable tool for the diagnosis of Basal cell carcinomas and prediction of their histopathological subtypes.",
      "score": 0.70799106
    },
    {
      "number": 16,
      "title": "Cutaneous Squamous Cell Carcinoma - StatPearls - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK441939",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov",
      "snippet": "for distant disease is necessary, via CT or PET. NCCN guidelines recommend baseline imaging (usually MRI with contrast) for patients with very-high-risk CSCC, including tumors >4 cm, depth of invasion >6 mm, perineural invasion involving nerves ≥0.1 mm, even if unnamed, given the risk for occult per",
      "score": 0.6102915
    },
    {
      "number": 17,
      "title": "Skin Cancer Treatment (PDQ®) - NCI",
      "detail": "tools.cdc.gov",
      "url": "https://tools.cdc.gov/podcasts/download.asp?m=343872&c=343882",
      "authors": "tools.cdc.gov",
      "host": "tools.cdc.gov",
      "snippet": "### Treatment of Basal Cell Carcinoma of the Skin (Localized Disease)\n\nTreatment options for BCC of the skin (localized disease) include:\n\n1. Surgical excision with margin evaluation.\n2. Mohs micrographic surgery.\n3. Radiation therapy.\n4. Curettage and electrodesiccation.\n5. Cryosurgery.\n6. Photodyn",
      "score": 0.80844593
    },
    {
      "number": 18,
      "title": "Basal cell carcinoma: an evidence-based treatment update",
      "detail": "pubmed.ncbi.nlm.nih.gov",
      "url": "https://pubmed.ncbi.nlm.nih.gov/24733429",
      "authors": "pubmed.ncbi.nlm.nih.gov",
      "host": "pubmed.ncbi.nlm.nih.gov",
      "snippet": "by CM Clark · 2014 · Cited by 175 — Treatment modalities reviewed include surgical therapy, radiotherapy and cryotherapy, photodynamic therapy (PDT), topical imiquimod, topical 5-fluorouracil",
      "score": 0.7144891
    },
    {
      "number": 19,
      "title": "Results - Treatments for Basal Cell and Squamous Cell Carcinoma of the Skin - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK487557",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov",
      "snippet": "by direct study comparisons as indicated by lines between the treatment circles. Most comparisons were covered by only a single RCT, and most treatments were compared with only one or two other treatments. Surgical excision was the most common comparator, being directly compared with imiquimod, MAL ",
      "score": 0.6912478
    },
    {
      "number": 20,
      "title": "Evaluation and Treatment of Skin Cancer in Patients With Immunosuppression - StatPearls - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/sites/books/n/statpearls/article-169493",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov",
      "snippet": "Systemic therapy is indicated when curative radiation therapy is not an option. Hedgehog signaling pathway inhibitors, such as vismodegib and sonidegib, are oral treatments for advanced BCCs. Vismodegib is approved by the US Food and Drug Administration (FDA) for all advanced BCCs, while sonidegib i",
      "score": 0.685971
    },
    {
      "number": 21,
      "title": "Management of basal cell carcinoma with pulmonary ...",
      "detail": "pubmed.ncbi.nlm.nih.gov",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36599494",
      "authors": "pubmed.ncbi.nlm.nih.gov",
      "host": "pubmed.ncbi.nlm.nih.gov",
      "snippet": "by SA Fordham · 2023 · Cited by 5 — Sonidegib, a hedgehog signalling inhibitor, was used for first-line treatment. Due to progressive disease, sonidegib was ceased. Cemiplimab",
      "score": 0.5533369
    },
    {
      "number": 22,
      "title": "Guidelines for the diagnosis and treatment of basal cell carcinoma: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S2059702923012784",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "of Medical Oncologists (AIOM) to assist clinicians in treating patients with BCC. They contain recommendations with regard to the diagnosis, treatment and follow-up, from primitive tumors to those locally advanced or metastatic, addressing the aspects of BCC management considered as priorities by a ",
      "score": 0.46993434
    },
    {
      "number": 23,
      "title": "Basal Cell Carcinoma Cell - an overview",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/topics/medicine-and-dentistry/basal-cell-carcinoma-cell",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "Review article\n\n## European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma—update 2023\n\n2023, European Journal of CancerKetty Peris, ... On behalf of EADO”A, EDF”B, ESTRO”C, UEMS”D and EADV”E\n\n### Abstract [...] Basal cell carcinoma (BCC) is the most ",
      "score": 0.45885846
    },
    {
      "number": 24,
      "title": "European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S0959804920300186",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "### J Am Acad Dermatol (2012) \n   National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. squamous cell skin cancer....\n   G. Work _et al._\n### Guidelines of care for the management of cutaneous squamous cell carcinoma\n\n### J Am Acad Dermatol (2018) \n   C. Newlands _et ",
      "score": 0.36724812
    }
  ],
  "publishedAt": "2026-08-24T17:03:21.432862+00:00",
  "updatedAt": "2026-08-24T17:03:21.432862+00:00",
  "readingMinutes": 5,
  "slug": "basal-cell-carcinoma"
}